期刊
TRENDS IN PHARMACOLOGICAL SCIENCES
卷 41, 期 8, 页码 531-543出版社
CELL PRESS
DOI: 10.1016/j.tips.2020.06.007
关键词
-
资金
- HUST COVID-19 Rapid Response Call [2020kfyXGYJ015]
Recent advances in the pathophysiologic understanding of the severe acute re- spiratory syndrome coronavirus 2 (SARS-CoV-2) infection has indicated that pa- tients with severe coronavirus disease 2019 (COVID-19) might experience cytokine release syndrome (CRS), characterized by increased interleukin (IL) -6, IL -2, IL -7, IL -10, etc. Therefore, the treatment of cytokine storm has been pro- posed as a critical part of rescuing severe COVID-19. Several of the cytokines in- volved in COVID-19 employ a distinct intracellular signaling pathway mediated by Janus kinases (JAKs). JAK inhibition, therefore, presents an attractive thera- peutic strategy for CRS, which is a common cause of adverse clinical outcomes in COVID-19. Below, we review the possibilities and challenges of targeting the in COVID-19.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据